Therapeutic area intelligence for Alpha-1 Blocker with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 0
Companies: 1

Companies

Aurobindo Pharma →

Assets

Aurobindo →

Recent signals(1)

StrategyAugust 8, 2026

Aurobindo Pharma's Doxazosin Mesylate Supplement Receives FDA AP Status

Aurobindo Pharma USA has received an Abbreviated New Drug Application (ANDA) approval for Doxazosin Mesylate.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.